InvestSMART

Invex Therapeutics Ltd (ASX:IXC)

ALERT: Price-sensitive ASX Announcement for IXC
Current share price for IXC : $0.110 -0.005 (-4.35%)+
Release
10 Nov 2025 9:37AM
Price at Release
$0.115
Full Release
download
Summary
Invex Therapeutics Ltd, a biopharmaceutical company focused on repurposing Exenatide for neurological treatments, announced several corporate changes. Simon Owen and Professor Warren Harding AM were appointed as non-executive directors following the resignation of David McAuliffe and Dr. Thomas Duthy. Simon Owen brings extensive legal and corporate advisory experience, while Warren Harding has significant leadership in global healthcare and biotech industries. Additionally, Carla Healy and Tim Slate were appointed as joint Company Secretaries, with Healy responsible for ASX communications. The company's registered office and principal place of business was relocated to Level 3, 101 St Georges Terrace, Perth WA 6000.
Key Points
  • Invex appoints Simon Owen and Professor Warren Harding AM as non-executive directors.
  • Carla Healy and Tim Slate named as joint Company Secretaries.
  • Company reforms board following the resignation of David McAuliffe and Dr. Thomas Duthy.
  • Registered office and principal place of business moved to Level 3, 101 St Georges Terrace, Perth WA 6000.
  • Invex focuses on repurposing Exenatide for treating neurological conditions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.